In particular, cerebral isoforms of CAs (mainly hCA I, II, VA, and VII) could be a valid target for the development of new agents useful for the treatment of neurodegenerative pathologies such as Alzheimer’s disease in which these isoforms showed to be less expressed. This evidence concerns the gene CYP24A1 and early-onset autosomal dominant Alzheimer disease.